ArticleScientific reports2026
A repurposing Dapagliflozin via polymeric nanogels for colorectal cancer therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dapagliflozin (DAPA), a selective SGLT2 inhibitor approved for type 2 diabetes, shows emerging potential for repurposing in oncology due to its anti-inflammatory and antiproliferative properties. However, its poor solubility and rapid systemic clearance limit its therapeutic utility in cancer treatment. Here, we report the development of an oral novel gravity-induced nano hydrogel mass system encapsulating DAPA using sodium alginate (SA) and polyvinyl alcohol (PVA) nanoparticles (DAPA-PVA-SA-NPs). The formulation exhibited enhanced solubility (1.8-fold increase), high encapsulation efficiency (88.37%), and sustained release in simulated gastrointestinal conditions. In vitro studies demonstrated improved cytotoxicity against HCT-116 colorectal cancer cells and significant downregulation of oncogenic and inflammatory markers (KRAS, IL-6, TGF-β, TNF-α). In vivo pharmacokinetic evaluation in rats showed delayed Tmax, extended half-life, and a 7% increase in AUC, indicating prolonged systemic exposure with modest AUC improvement. This delivery platform improves oral exposure in rats, shows in vitro activity in HCT-116 cells and supporting further exploratory evaluation for repurposing DAPA in colorectal cancer, pending confirmation in additional models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.